Here's Why Agenus Inc. Stock Slipped 13.6% in July
Shares of Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, fell 13.6% in July according to data from S&P Global Market Intelligence. Investors viewed a clinical-trial failure reported by AstraZeneca as a harbinger of sorrow for similar candidates in its own pipeline.
Aside from an adjuvant featured in GlaxoSmithKline's shingles-vaccine candidate, Agenus Inc.'s future hinges on success for new drug candidates that inhibit a cancer cell's ability to exploit the CTLA-4 and PD-1 immune-response checkpoints. This is why the market beat up Agenus when AstraZeneca reported its combination of tremelimumab, which blocks CTLA-4, and Imfinzi, which blocks PD-1, failed to provide a significant survival benefit compared to standard chemotherapy for previously untreated patients with stage-four lung cancer.
Image source: Getty Images.
Source: Fool.com
Agenus Inc. Stock
Our community is currently high on Agenus Inc. with 4 Buy predictions and 2 Sell predictions.
Based on the current price of 0.41 € the target price of 36 € shows a potential of 8599.86% for Agenus Inc. which would more than double the current price.
